Rosetta Genomics Fortifies Patent Position With U.S. Allowance Of Claims Covering Human MicroRNAs MiR-21 And Hcmv-miR … (Medical News Today)
Rosetta Genomics Fortifies Patent Position With U.S. Allowance Of Claims Covering Human MicroRNAs MiR-21 And Hcmv-miR … (Medical News Today)
Rosetta Genomics (NASDAQ:ROSG) today announced that the United States Patent and Trademark Office has allowed claims in two patent applications. The first, covering human microRNA miR-21, was derived from the “Tuschl III” patent series that is assigned to the Max Planck Society, Berlin, Germany and is used in Rosetta’s miRview mets and miRview squamous diagnostic assays. Rosetta holds a co …